---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017657"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T18:49:42.286652+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protalix Q3 revenues from goods up 16% to $10.2M; net loss narrows to $1.9M

## Summary
- Revenues from selling goods $10.2M (+16% YoY), driven by Elfabrio sales to Chiesi after FDA/EMA approvals.
- License and R&D service revenues fell 96% to $0.2M as extension studies transferred to Chiesi.
- Net loss improved to $1.9M ($0.03 basic EPS) vs $3.6M loss ($0.07 EPS) in Q3 2022.
- Cash and equivalents $41.0M; PRX-115 Phase I for gout enrolled 32 patients, results expected mid-2024.
- Regulatory: UK MHRA and Swissmedic approved Elfabrio; Dr. Eliot Forster appointed Board Chairman.

## SEC filing metadata
- accession: 0001558370-23-017657
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023017657/0001558370-23-017657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023017657/plx-20231106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017657
- JSON: https://secwatch.observer/filing/0001558370-23-017657.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017657.txt

## Key facts
- Earnings Releases
  Protalix BioTherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 6, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023017657/0001558370-23-017657-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.